Statin therapy: long-term mortality and cancer incidence
This article has no abstract so we have provided the first paragraph of the full text.
The Scandinavian Simvastatin Survival Study (4S), which ended in 1994, demonstrated that cholesterol-lowering with simvastatin reduced the rates of coronary events and all-cause mortality. Following the trial, which included a median follow-up period of 5.4 years, most patients received open-label lipid-lowering treatment. Strandberg et al. now report on their 5-year extended follow-up, which studied cause-specific mortality and cancer incidence after the end of the double-blind follow-up period.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mathematical physics Added dimensions to grain growthNature News and Views (26 Apr 2007)
Solar size variationNature News and Views (31 Jul 1980)
DisSARMing Toll-like receptor signalingNature Immunology News and Views (01 Oct 2006)